Home Patent Forecast® Sectors Log In   Sign Up   Free Trial   Support   Contact   Pricing  
Enjoy your FREE PREVIEW which shows only 2020 data and 25 documents. For full access, try it free at any time.        

Cannabis: Compositions

Zynerba Pharmaceuticals, Inc.


Zynerba is developing transdermal cannabis drugs and prodrugs for the treatment of Fragile X syndrome, autism spectrum disorder, developmental and epileptic encephalopathies, and 22q. As of July 2021, its patented Zygel™ topical CBD gel has not been approved by government agencies in the US. 

News and Insights

Zynerba Pharmaceuticals, Inc. Owned Patent Documents in this Patent Forecast
Loading Documents...